Showing 2411-2420 of 3134 results for "".
- Revian: USPTO Grants Patent for Biostimulatory Approachhttps://modernaesthetics.com/news/regina-uspto-grants-patent-for-biostimulatory-approach/2472862/The United States Patent and Trademark Office (USPTO) has awarded to Revian Inc. U.S. Patent No. 10,265,258—the seminal patent on the use of proprietary color combinations of light to regenerate living tissue in the body. The claims in this issued patent cover the use
- BTL Files Patent Infringement Lawsuit Against Allergan and Zimmer Related to Emsculpthttps://modernaesthetics.com/news/btl-files-patent-infringement-lawsuit-against-allergan-and-zimmer-related-to-emsculpt/2472855/BTL Aesthetics' US affiliate has filed a lawsuit against Allergan plc, Ireland and its affiliates, and Zimmer MedizinSysteme GmbH, Germany, and its affiliate, in the US Federal District Court for the District of Delaware. The lawsuit asserts
- Alastin Skincare Receives Third Patenthttps://modernaesthetics.com/news/elastin-skincare-receives-third-patent/2472853/Alastin Skincare, Inc. has received a third US Patent from the United States Patent and Trademark Office. The patent covers Alastin’s innovative science and products. US Patent No. 10,493,011 is entitled, "Peptide Compositions and Methods for Ameliorating Skin Laxity and Bod
- Revance's DAXI Now One Step Closer to FDA Nodhttps://modernaesthetics.com/news/revances-daxi-now-one-step-closer-to-fda-nod/2472849/Revance Therapeutics, Inc. has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for DaxibotulinumtoxinA for Injection (DAXI) in the treatment of moderate to severe glabellar lines. Under
- It's A Deal: Baring Private Equity Asia Agrees to Acquire Lumenishttps://modernaesthetics.com/news/its-a-deal-baring-private-equity-asia-agrees-to-acquire-lumenis/2472848/Baring Private Equity Asia’s affiliated private equity funds are acquiring Lumenis. The transaction, which values Lumenis at an enterprise value of more than $1 billion, remains subject to the customary regulatory approval process. It is expected to be completed in early 2020. <
- Business News: Hologic to Offload Cynosure for $205Mhttps://modernaesthetics.com/news/business-news-hologic-to-offload-cynosure-for-205m/2472847/Hologic is selling Cynosure medical aesthetics business to an affiliate of investment funds managed by Clayton, Dubilier & Rice for a total purchase price of $205 million in cash, subject to certain closing adjustments. This is a tenth of the $1.6B that Hologic, a women
- Update: Instagram Removes Cosmetic Surgery Filtershttps://modernaesthetics.com/news/update-instagram-removes-cosmetic-surgery-filters/2472841/In a move designed to promote mental well being, Instagram, owned by Facebook, is removing all augmented reality filters that depict cosmetic surgery. In addition, the social media giant is striking all effects from the gallery that are associated with plastic surgery and postponing the
- Obagi at ASDS: Panel to Focus on Inclusionhttps://modernaesthetics.com/news/obagi-at-asds-panel-to-focus-on-inclusion/2472833/Obagi and actor, producer and activist, Priyanka Chopra Jonas, will lead a panel of top dermatologists in a discussion about the importance of diversity and inclusion in medical aesthetics during the annual meeting of the American Society for Dermatologic Surgery (ASDS) in Chicago next week. 
- Happy 30th, Botox!https://modernaesthetics.com/news/happy-30th-botox/2472832/Botox is turning 30, and Allergan fêted its shining star, Botox Cosmetic, in style at a New York City bash. The event included the debut of Botox Cosmetic’s new packaging and a panel discussion featuring New York City dermatologists Macrene Alexiades-Armenakas, MD, PhD
- Data Support Benefits of Natural Skincare: Burt's Beeshttps://modernaesthetics.com/news/data-support-benefits-of-natural-skincare-burts-bees/2472826/Products and ingredients in the Burt’s Bees natural skincare line provide documented benefits, according to studies presented at the second annual Integrative Dermatology Symposium (IDS) in San Diego this month. Among the findings is evidenc